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Abstract 
Background: The coverage of prevention and treatment strategies for ischemic heart disease and stroke is very low 
in Ethiopia. In view of Ethiopia’s meager healthcare budget, it is important to identify the most cost-effective interven-
tions for further scale-up. This paper’s objective is to assess cost-effectiveness of prevention and treatment of ischemic 
heart disease (IHD) and stroke in an Ethiopian setting.
Methods: Fifteen single interventions and sixteen intervention packages were assessed from a healthcare provider 
perspective. The World Health Organization’s Choosing Interventions that are Cost-Effective model for cardiovascular 
disease was updated with available country-specific inputs, including demography, mortality and price of traded 
and non-traded goods. Costs and health benefits were discounted at 3 % per year. Incremental cost-effectiveness 
ratios are reported in US$ per disability adjusted life year (DALY) averted. Sensitivity analysis was undertaken to assess 
robustness of our results.
Results: Combination drug treatment for individuals having >35 % absolute risk of a CVD event in the next 10 years 
is the most cost-effective intervention. This intervention costs US$67 per DALY averted and about US$7 million annu-
ally. Treatment of acute myocardial infarction (AMI) (costing US$1000–US$7530 per DALY averted) and secondary 
prevention of IHD and stroke (costing US$1060–US$10,340 per DALY averted) become more efficient when delivered 
in integrated packages. At an annual willingness-to-pay (WTP) level of about US$3 million, a package consisting of 
aspirin, streptokinase, ACE-inhibitor and beta-blocker for AMI has the highest probability of being most cost-effective, 
whereas as WTP increases to > US$7 million, combination drug treatment to individuals having >35 % absolute risk 
stands out as the most cost-effective strategy. Cost-effectiveness ratios were relatively more sensitive to halving the 
effectiveness estimates as compared with doubling the price of drugs and laboratory tests.
Conclusions: In Ethiopia, the escalating burden of CVD and its risk factors warrants timely action. We have dem-
onstrated that selected CVD intervention packages could be scaled up at a modest budget increase. The level of 
willingness-to-pay has important implications for interventions’ probability of being cost-effective. The study provides 
valuable evidence for setting priorities in an essential healthcare package for CVD in Ethiopia.
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Background
Cardiovascular disease (CVD) is the leading cause of 
mortality globally. The Global Burden of Disease study 
estimated that about 32 % of all deaths worldwide in 2013 
were caused by CVD [1], with about 80 % of these deaths 
occurring in low-and middle-income countries (LMIC) 
[1, 2].
Approximately 9  % of all deaths in Ethiopia in 2012 
were caused by CVD according to World Health Organi-
zation (WHO) estimates [3]. Small-scale local stud-
ies also reported an increasing burden from CVD and 
its risk factors, especially in urban settings in Ethiopia 
[4–15]. In a systematic review of studies conducted in 
Ethiopia between 1960 and 2011, CVD was reported to 
be among: (a) the prevalent causes of morbidity (range 
4–24 %); (b) the main causes of hospital admission, espe-
cially among those older than 60 years (range 3–31 %); (c) 
the leading causes of medical intensive care unit admis-
sion (range 8.9–9.8 %); and (d) among the major causes 
of mortality (range 6.5–24  %) [15]. In Ethiopia’s capital, 
Addis Ababa, an estimated 25 % of all household deaths 
between 2006 and 2009 and 11  % of all hospital deaths 
between 2002 and 2010 were attributed to CVD [7, 8]. 
Myocardial infarction, stroke and hypertensive heart 
disease accounted for about 75 % of CVD deaths [7, 8]. 
Modifiable risk factors like smoking, high cholesterol and 
high blood pressure explain the major share of the CVD 
burden [16, 17]. The prevalence of hypertension in Ethio-
pia is estimated to range from 16 to 30 % [5, 6, 13, 14].
WHO recommends a combination of population-wide 
and individual-based prevention and basic treatment 
strategies for successful control of CVD [18, 19]. Cur-
rent coverage of such interventions is low in Ethiopia. 
Only about a quarter of the patients diagnosed with CVD 
at two referral hospitals in Ethiopia were found to be on 
medication [6, 9].
Cognizant of the increasing burden from non-commu-
nicable diseases (NCDs), the Federal Ministry of Health 
of Ethiopia (FMOH) has launched a National Strategic 
Action Plan (NSAP) for Prevention and Control of NCDs, 
envisioning the scale-up of an essential package of NCD 
interventions targeting the four major NCDs, including 
CVD [20]. With Ethiopia’s meager health spending of 
only about US$ 21 per capita per year in 2011 [21], it is 
imperative to identify the most efficient strategies for fur-
ther scale-up.
Cost-effectiveness analysis is a key tool to assist policy 
makers in selecting the most efficient strategy among 
competing alternatives. WHO-CHOICE (Choosing Inter-
ventions that are Cost-Effective) has undertaken cost-
effectiveness analysis of CVD interventions for the major 
regions in low- and middle-income countries [22–24]. 
Regional estimates have limited relevance to country-level 
decision making due to variation in key parameters. 
Parameters such as demography, epidemiology, costs and 
coverage of interventions vary widely across countries 
within the same regions, warranting the need for local 
evidence for better decision-making [23, 25–27]. To our 
knowledge there is no local evidence on cost-effectiveness 
of CVD interventions in Ethiopia. We therefore intend 
to fill this knowledge gap and inform the process of evi-
dence-based resource allocation and priority setting for 
essential package for CVD interventions in Ethiopia.
This paper’s objective is to undertake a cost-effective-
ness analysis of primary prevention, acute treatment and 
secondary prevention of ischemic heart disease (IHD) 
and stroke in an Ethiopian setting.
Methods
We performed a generalized cost-effectiveness analysis 
of prevention and treatment strategies for CVD in an 
Ethiopian setting based on the WHO-CHOICE approach 
whereby, cost-effectiveness of each intervention is 
assessed compared with a ‘no intervention’ scenario [28]. 
Box  1 below depicts key socio-demographic and eco-
nomic indicators for Ethiopia. A brief description of the 
interventions assessed, the modeling approach and the 
country-specific revisions are outlined below.
Box  1 Key socio-demographic and  economic parameters 
for Ethiopia, 2013/14
Parameter Level Source
Total population 96.96 million
Life expectancy at birth 64 years [29]
GDP per capita US$505
Currency exchange rate to US$ 17.7
PPP exchange rate 7.08
Total health expenditure (annual) US$1.6 billion
Per capita spending on health (annual) US$21 [21]
Number of health facilities [30]
 Hospital 189
 Health center 3547
 Health post 16,251
Interventions
Fifteen single interventions and sixteen integrated inter-
vention packages were assessed. Interventions target 
individuals without a history of established CVD but at 
risk of developing a CVD event; those with an acute CVD 
event; and those with a history of established CVD event. 
Interventions were selected based on the recommenda-
tions of WHO and local experts and scientific evidence of 
effectiveness. Full description of the interventions is out-
lined in Table 1.
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For primary prevention, individual-based drug regi-
mens based on either the level of systolic blood pressure 
(SBP), the level of total serum cholesterol or the absolute 
risk of developing a CVD event over the next 10  years 
were assessed. Absolute risk is determined based on well-
known CVD risk factors (age, gender, SBP, smoking sta-
tus, body mass index and total serum cholesterol level) 
[18, 19]. The distribution  of mean risk factor levels and 
smoking status in the population was stratified by age 
and gender based on the estimates from WHO’s Com-
parative Risk Assessment project for East Africa region. 
Estimates of relative risk of developing a CVD event per 
unit increase in the level of risk factors was then applied 
to estimate the individual level relative risk of developing 
a CVD event which is then used to extrapolate the abso-
lute risk of CVD event at population level [19, 31]. The 
drug regimens are to be delivered on an outpatient basis 
at health centers and constitute: (a) a beta-blocker and a 
diuretic at SBP of >140 mmHg or >160 mmHg; (b) sta-
tin treatment at serum cholesterol level of  >5.7  mmol/l 
or  >6.2  mmol/l; and (c) a combination of aspirin, beta-
blocker, diuretic and statin-based on the absolute risk of 
a CVD event for four thresholds (>5, >15, >25 or >35 %) 
respectively.
Interventions for acute myocardial infarction (AMI) 
constitute treatment with aspirin, streptokinase, clopi-
dogrel, beta-blocker, ACE-inhibitor and surgical revascu-
larization with percutaneous coronary intervention (PCI) 
on an inpatient basis. Aspirin is used for acute treat-
ment of ischemic stroke; and beta-blocker, aspirin, ACE-
inhibitor and statin for secondary prevention of IHD and 
stroke. Interventions were first assessed individually; 
clinically relevant packages were then formed, building 
on the intervention with the lowest cost-effectiveness 
ratio.
Given the current low coverage of interventions—
less than 5  %, based on experts’ recommendations—
we set modest target coverage of 20  % for all of the 
interventions.
In the absence of local evidence, efficacy estimates were 
drawn from previous randomized controlled trials and 
meta-analyses performed elsewhere (Table  2) [32–46]. 
Efficacy estimates were adjusted by target coverage and 
patient adherence level [47–49].
Modeling approach
The WHO-CHOICE’s CVD model for East Africa was 
used to undertake the analysis [50]. The model was 
updated with age and sex distribution, birth rate and 
background mortality rate for Ethiopia [51–53]. In the 
absence of national data on the current level of incidence, 
prevalence and mortality rates of IHD and stroke and 
the distribution of CVD risk factors, the analysis used 
respective estimates for the East Africa region [22, 23, 31, 
50, 52].
The effect of primary prevention interventions is mod-
eled through their impact on the level of risk factors, 
which is used to recalculate the expected incidence rate 
for IHD and stroke after implementing the specific inter-
vention. The new incidence rate is applied to estimate 
the reduction in mortality from the respective diseases. 
Interventions targeting AMI and acute stroke were mod-
eled through the interventions’ impact on 28-day case 
fatality rate, while secondary prevention interventions 
were modeled through their impact on post–acute case 
fatality rate. The effect of interventions was assumed to 
be the same across sub-groups.
We used PopMod, a multi-state population model, 
to estimate the health benefits in disability adjusted 
life years (DALYs) averted for the Ethiopian popula-
tion resulting from changes in CVD risk due to specific 
interventions.
The population in the model is divided into age–sex 
categories of one-year intervals which are further strati-
fied into four health states: (a) those having IHD; (b) 
those having stroke; (c) those having both; and (d) those 
without any of the conditions. Transition between states 
is dictated by the respective incidence, case fatality and 
mortality rates. Disability weights for the health states 
were drawn from the Global Burden of Disease Study 
2010 [54]. PopMod traces the changes in population size 
in each age–sex category over a lifetime of 100 years by 
standard life table methods with and without specific 
interventions (‘no intervention’ scenario). Interventions 
are implemented for 10  years, after which the epidemi-
ologic rates are taken back to the ‘no intervention’ level. 
Births and background mortality are taken into account 
[31, 55]. The expected health benefits of the current cov-
erage level of interventions are eliminated to create a 
hypothetical reference case of null scenario. The model 
provides removal of the benefits of current coverage 
of interventions, thereby allowing recalculation of the 
incidence, prevalence and case fatality rates for MI and 
stroke, assuming a scenario where the currently imple-
mented interventions are stopped. The health benefits 
are reported in terms of DALYs averted, discounted at 
3 % per year without age weighting. The model has been 
used to undertake CEAs of various interventions in mul-
tiple settings [22]; and details have been published else-
where [23, 24, 55].
Costs
A healthcare provider perspective was used for analysis 
and hence only program costs, training costs and patient-
related costs to the provider were taken into account. 
Program costs constitute the cost of development and 
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administration of an intervention at national and sub-
national levels. This includes cost of administration and 
planning, media and communication, law enforcement, 
training, monitoring and evaluation. Patient-related costs 
consist only of direct medical costs incurred by the pro-
vider at the point of service delivery, including hospital 
bed days, outpatient visits, drugs and laboratory [28]. 
The analysis did not include direct non-medical costs 
such as transportation and indirect costs to patients 
and care givers such as lost productivity. The ingredi-
ents costing approach was employed whereby the quan-
tities of resources required to deliver the interventions 
and respective unit prices were accounted for separately 
(Table  3). The quantities of resources used were largely 
determined based on WHO-CHOICE assumptions. We 
updated the prices of relevant laboratory tests and imag-
ing using pricing from two public hospitals in Addis 
Ababa (Tikur Anbessa teaching hospital and Zewditu 
hospital). Salary scale of the health workforce was based 
on the FMOH of Ethiopia. Equipment and material prices 
were based on WHO price estimates for Ethiopia for the 
year 2012/13 [56] and drug prices were based on the 
lowest supplier prices for 2012, as noted in the Interna-
tional Drug Price Indicator Guide [57]. WHO-CHOICE’s 
transport multiplier factor was applied to the drug prices. 
The total cost of an intervention was then calculated as 
the sum of the product of the quantities of resources with 
their respective unit prices. As recommended by WHO-
CHOICE costs were discounted at an annual rate of 3 % 
[28] and reported in 2012 US$.
Cost‑effectiveness
All interventions were assessed compared to ‘no inter-
vention’ scenario first, followed by incremental analysis 
between mutually exclusive interventions. Average cost-
effectiveness ratios (ACERs) were estimated dividing the 
incremental cost by incremental effects of each interven-
tion compared with a ‘no intervention’ scenario. In order 
to assess the relative cost-effectiveness of mutually exclu-
sive interventions, incremental cost-effectiveness ratios 
(ICERs) were estimated as the ratio of the incremental 
cost to incremental effects for moving from one inter-
vention to the next more effective intervention, starting 
from the null scenario. Interventions that are more costly 
and less effective than their comparators or those having 
higher ICER than their more effective comparator are 
designated as dominated. ACERs and ICERs are reported 
in US$ per DALY averted for the year 2012.
Table 2 Effectiveness assumption used in the model expressed in percentage reduction in the outcome of interest
Intervention Outcome affected Efficacy in % Source
Acute myocardial infarction
 Aspirin 28 day mortality 22 (15, 29) [31, 36]
 ACE-inhibitor 28 day mortality 7 (2, 11) [37, 40]
 Beta-blocker 28 day mortality 13 (2, 23) [37, 40]
 Streptokinase 28 day mortality 26 (17, 31) [36]
 ASA + clopidogrel 28 day mortality 32 (17, 47) [31, 34]
 PCI 28 day mortality 61 (38, 75) [33, 36, 41]
Post-acute myocardial infarction
 Aspirin Case fatality rate 13 (2, 22) [31, 66]
 ACE-inhibitor Case fatality rate 23 (14, 30) [42]
 Beta-blocker Case fatality rate 23 (16, 30) [43]
 Statin Case fatality rate 19 (15, 24) [44, 67]
Acute ischemic stroke
 Aspirin 28 day case fatality rate 5 (1, 9) [31]
Post-acute stroke
 Aspirin Case fatality rate 16 (2, 29) [31]
 ACE-inhibitor Case fatality rate 16 (12, 30) [45]
 Statin Case fatality rate 24 (16, 37) [35]
Primary prevention of IHD and stroke
 Anti-hypertensive treatment for systolic blood pres-
sure (>140 or >160 mmHg)
Difference between actual systolic blood pressure 
and 115 mmHg
33 (31, 44) [40, 46, 68]
 Cholesterol lowering treatment for total cholesterol 
(>5.7 or >6.2 mmol/l)
Serum level of total cholesterol 20 (17, 23) [27, 44]
 Combination drug treatment for absolute risk of 
CVD (>5, >15, >25, >35 %)
Effect on the level of systolic blood pressure plus 
serum cholesterol plus aspirin
(33) + (20) + (18) [27, 40, 44, 46, 66, 68]
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Uncertainty analysis
A probabilistic sensitivity analysis was conducted using 
Monte Carlo League (MCLeague) software to assess the 
effect of uncertainty surrounding the costs and effec-
tiveness estimates [58]. A truncated normal distribution 
was used to execute 1000 simulation runs with 15 and 
25  % coefficient of variation for costs and effectiveness 
estimates, respectively. We assessed interventions that 
were not dominated by respective comparators in each 
intervention category. In addition, one-way sensitivity 
analysis was undertaken, applying the lower boundary 
of the effectiveness range; doubling the price of drugs, 
procedures and laboratory tests; a zero discounting rate 
to health benefits; and applying 50 % of the effectiveness 
point estimates (Tables 1, 2).
Results
Treatment of acute myocardial infarction with ACE-
inhibitor costs the least at US$2.4 million annually. 
Combination drug treatment to individuals having >5 % 
absolute risk of developing a CVD event incurs the high-
est annual cost US$26.9 million— and generates the 
highest annual health benefit of 190,000 DALYs averted. 
Treatment of acute stroke with aspirin generates the 
smallest annual health benefit. The estimated annual 
costs, health benefits, ACER and ICERs for all interven-
tions are presented in Table 4 below.
The absolute risk-based approach turns out to be the 
most cost-effective strategy of all the interventions. 
Combination drug treatment to individuals having an 
absolute risk >35 % yields the most value for money with 
an ICER of US$67 per DALY averted, with ICER reach-
ing US$340 per DALY averted when the risk threshold is 
lowered to >5 %. When compared with the single risk–
factor based approach, the absolute risk-based approach 
is the most cost-effective option. Notably, initiating 
treatment at higher CVD risk threshold generates bet-
ter efficiency gain compared to lower risk thresholds 
regardless of the approach chosen. This means, for 
example, that initiating anti-hypertensive drug treat-
ment at SBP of >160 mmHg is more efficient than treat-
ment at >140 mmHg. Of all the interventions for AMI, 
an integrated package of aspirin, ACE-inhibitors, beta-
blockers and streptokinase has the lowest ICER (i.e., 
US$999 per DALY averted). Provision of interventions 
in an integrated package generates better efficiency gain 
and dominates all the single interventions, as shown in 
Table  4. Moving from the most cost-effective pharma-
ceutical package to an integrated package that includes 
the highly skilled intervention PCI, aspirin and clopi-
dogrel raised the ICER substantially—to US$5087 per 
one additional DALY averted.
Treatment of acute ischemic stroke with aspirin costs 
US$40,000 per DALY averted. Single drug interventions 
for secondary prevention of IHD and stroke cost between 
US$2400 and US$10,300 per DALY averted respectively. 
Interventions become more efficient when delivered in 
an integrated package. A package consisting of aspirin, 
beta-blocker ACE-inhibitor and statin for secondary pre-
vention of IHD costs US$1850 per DALY averted, while a 
package consisting of aspirin, ACE-inhibitor and statins 
for secondary prevention of stroke costs US$1060 per 
DALY averted.
Table 3 Price of  intervention inputs applied in  the model 
in Ethiopian birr 2012
a Unit price per procedure. The program cost was assumed to be double the 
program cost required for other acute myocardial infarction interventions
Unit price Unit price
Salary scale for human resource
 Medical specialist 112,781 Director of public 
health
51,293
 Medical officer 76,723 Public health specialist 94,712
 Nursing director/
manager
64,728 Public health assistant 28,339
 Registered nurse 28,339 Health educator/
trainer
28,339
 Health worker 51,293 Social/welfare worker 28,339
Source: Federal Ministry of Health, Ethiopia 2012
Health facility visit/stay
 Hospital bed days Health facility visit
 Primary hospital 52.52  Primary hospital visit 18.58
 Secondary hospital 54.76  Secondary hospital 
visit
21.17
 Tertiary hospital 70.81  Tertiary hospital visit 22.06
 Percutaneous coronary interven-
tiona 63,000
 Health center visit 23.00
Source: WHO_CHOICE [69]
Laboratory and imaging
 Complete blood 
count
20 Blood glucose 10
 Prothrombin time 
(INR)
15 Urinalysis 5
 aPTT 15 Liver function test 30
 Serum electrolytes 45 Total cholesterol 7
 Renal function test 20 Serum lipids 42
 Blood glucose 10 CT scan 600
 Echocardiography 150 Endoscopy 400
Source: Tikur Anbesa teaching hospital and Zewditu memorial hospital
Drugs
 ASA 100 mg 0.08 Simvastatin 20 mg 0.25
 Enalapril 10 mg 0.05 Streptokinase 1.5 iu 601.8




Source: International drug price indicator [57]
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Table 4 Annual cost, annual health benefits and cost-effectiveness ratio of selected CVD interventions in Ethiopia
Intervention description Annual cost in  
million US$
Annual DALYs averted  
(discounted)




 ACE-inhibitor 2.37 316 422 7531 Dominated
 Beta-blocker 2.38 586 784 4057 Dominated
 ASA 2.38 990 1325 2200 Dominated
 Streptokinase 2.82 1170 1566 2408 Dominated
 ASA + clopidogrel 2.38 1441 1927 1556 Dominated
 ASA + streptokinase 2.84 2110 2822 1295 Dominated
 ASA + streptokinase + ACE-
inhibitor
2.85 2396 3205 1149 Dominated
 Primary PCI 8.29 2747 3675 3013 Dominated
 ASA + streptokinase + ACE-
inhibitor + beta-blocker
2.92 2919 3905 999 999
 ASA + clopidogrel + PCI 8.5 4015 5370 2115 5087
Acute stroke
 ASA 2.53 63 80 39,892 39,892
Post-acute IHD
 ASA 2.54 245 330 10,345 Dominated
 Statin 2.74 310 417 8822 Dominated
 Beta-blocker 2.53 488 657 5177 Dominated
 ACE-inhibitor 2.55 524 705 4857 Dominated
 ASA + beta-blocker 2.57 732 985 3511 Dominated
 ASA + beta-blocker + statin 2.82 1038 1397 2717 Dominated
 ASA + beta-blocker + sta-
tin + ACE-inhibitor
2.88 1557 2096 1849 1849
Post-acute stroke
 ACE-inhibitor 2.87 912 1200 3153 Dominated
 ASA 2.86 1013 1348 2821 Dominated
 Statin 3.30 1375 1813 2396 Dominated
 ASA + statin 3.40 2382 3150 1428 Dominated
 ASA + statin + ACE-inhibitor 3.48 3284 4337 1061 1061
Primary prevention of IHD and stroke
 Cholesterol lowering 
treatment for total 
chol. >6.2 mmol/l
4.67 8768 15,913 532 Dominated
 Cholesterol lowering 
treatment for total 
chol. >5.7 mmol/l
10.62 19,073 34,143 557 Dominated
 Anti-hypertension treatment 
for SBP >160 mmHg
7.33 98,880 172,868 74 Dominated
 Combination drug treat-
ment for absolute risk of 
CVD >35 %
7.18 107,687 185,249 67 67
 Anti-hypertension treatment 
for SBP >140 mmHg
19.42 125,712 220,992 154 Dominated
 Combination drug treat-
ment for absolute risk of 
CVD >25 %
9.83 127,957 219,230 77 131
 Combination drug treat-
ment for absolute risk of 
CVD >15 %
14.41 153,877 263,747 94 177
 Combination drug treat-
ment for absolute risk of 
CVD >5 %
26.85 190,391 329,117 141 341
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In order to facilitate step-wise selection of the most 
cost-effective interventions, interventions that dominate 
their comparators in each category were ranked accord-
ing to their category-specific ICER. Accordingly, com-
bination drug treatment to individuals having  >35  % 
absolute risk of developing a CVD event is the first inter-
vention to be selected, followed by the same intervention 
at lower risk thresholds (>25, >15 and >5 %, respectively). 
A basic integrated package of aspirin, ACE-inhibitor, 
beta-blocker and streptokinase for AMI and a package of 
aspirin, statin and ACE-inhibitor for secondary preven-
tion of stroke are the next two interventions that could be 
selected when more resources become available. Scale-up 
of combination drug treatment at an absolute risk >35 % 
to a coverage level of 20 % costs about US$7 million per 
year and averts 107,000 DALYs annually.
Table 5 presents the results from the one-way sensitiv-
ity analysis. At the lower boundary of the effectiveness 
range, all interventions become less cost-effective. The 
ACERs increased by a factor of 1.5-to sixfold for AMI 
and secondary prevention interventions. Primary pre-
vention interventions were less sensitive. Halving the 
point estimates for effectiveness has a relatively larger 
impact on the primary prevention interventions, with 
respective ACERs increasing by a factor of 1.4–1.8. How-
ever, even at half point estimate of effectiveness, combi-
nation drug treatment to individuals having >35 % CVD 
risk costs US$94 per DALY averted. Doubling the price 
of drugs and laboratory tests increases ACERs minimally 
compared with halving or applying lower limit of effec-
tiveness estimates. All the interventions become more 
cost-effective at a zero discounting rate for the health 
benefits (Table 5).
The probabilistic sensitivity analysis illustrates the seri-
ous uncertainty surrounding our results, with wide and 
overlapping uncertainty ranges for cost and effectiveness 
estimates (Fig. 1). Budget size has considerable impact on 
the probability of interventions being cost-effective. At 
an annual budget of US$3–US$4 million, an integrated 
package consisting of ASA, streptokinase, ACE-inhibitor 
and beta-blocker for AMI has the highest probability 
(0.50) of being the most cost-effective approach. Between 
US$4 and US$7 million, the probability curve for a sec-
ondary prevention package for stroke consisting of aspi-
rin, ACE-inhibitor and statin overlaps on the basic AMI 
package, making the choice less straight forward. As the 
budget increases to more than US$7 million per year, 
combination drug treatment to individuals having more 
than 35  % absolute risk of CVD stands out as the most 
cost-effective intervention. However, even at this budget 
level, the other interventions have less but meaningful 
probability of being cost-effective (Fig. 2). 
Discussion
Our analysis illustrates that primary prevention of 
ischemic heart disease and stroke is a more efficient 
strategy for maximizing population-level health benefits 
compared with acute treatment and secondary preven-
tion. All primary prevention interventions cost less than 
US$ 560 per DALY averted. The absolute risk-based 
approach is more cost-effective than the single risk-factor 
approaches for primary prevention of CVD. This corre-
sponds with the findings of similar studies for the sub-
Saharan Africa region and other regions [23, 24]. The 
superiority of the absolute risk-based approach is primar-
ily explained by: (a) the linear nature of the correlation 
between blood pressure and cholesterol level with the 
risk of CVD event and (b) the tendency for co-existence 
and interaction between CVD risk factors [19, 59, 60]. 
The modest ‘efficiency loss’ related to lowering the risk 
thresholds is due to the larger number of eligible individ-
uals significantly increasing the cost for a relatively mod-
est additional health benefits. It is therefore worthwhile 
to set the CVD risk threshold at >35 % initially; this can 
be lowered when more resources become available. The 
proposed risk threshold of  >35  % accords with WHO’s 
recommendation for resource-limited settings like Ethio-
pia [18].
All the single pharmacologic interventions for treat-
ment of AMI were dominated by the integrated pack-
age consisting of aspirin, ACE-inhibitor, beta-blocker 
and streptokinase. Delivering interventions in integrated 
packages yields significant efficiency gain due to savings 
from program costs and patient costs [23]. This is compa-
rable with the results from the Disease Control Priorities 
project 2nd edition [61]. Interestingly, the ICER escalates 
by about six fold if one moves from this basic pharma-
ceutical package to a highly skilled intervention consist-
ing of PCI, aspirin, and clopidogrel. Although PCI is the 
treatment of choice for AMI in ideal settings [41, 62], our 
results indicate the need to prioritize the scale-up of basic 
pharmacologic regimens for AMI treatment in resource-
constrained settings like Ethiopia rather than investing 
the limited resources on high-standard interventions.
An integrated package of aspirin, beta-blocker, ACE-
inhibitor and statin for secondary prevention of IHD 
and a package of aspirin, ACE-inhibitor and statin for 
secondary prevention of stroke appears to be the pre-
ferred options within their categories. This is in line with 
the findings of Ortegon et al. for the sub-Saharan Africa 
region [23]. On the grounds of cost-effectiveness, sec-
ondary prevention interventions are ranked lower than 
primary prevention interventions. This is partly because 
primary prevention interventions generate a larger pop-
ulation-level aggregate health benefit with relatively 
lower unit delivery costs [23]. In addition, the need for 
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Table 5 Average cost-effectiveness ratios for cardiovascular disease interventions under multiple scenarios
a Undiscounted health benefits
b 10 % target coverage
c Double price for drugs, procedures and laboratory test
d Lower boundary of effectiveness estimate
e 50 % of point estimate of effectiveness
Intervention description Base‑case Undiscounted 
health benefitsa
10 % coverageb Double costc Lower effectd 50 % effecte
Acute myocardial infarction
 ACE-inhibitor 7526 5626 14,718 7777 26,556 15,172
 Beta-blocker 4054 3031 7926 4191 26,556 8171
 ASA 2398 1792 4685 2480 3545 4831
 Streptokinase 2407 1799 4343 2855 3714 4850
 ASA + clopidogrel 1652 1235 3225 1712 2958 3327
 ASA + streptokinase 1345 1006 2419 1603 2015 2669
 ASA + streptokinase + ACE-inhibitor 1188 888 2133 1411 1903 2342
 Primary PCI 3013 2252 4560 4460 4833 5983
 ASA + streptokinase + ACE-inhibi-
tor + beta-blocker
998 746 1774 1210 1839 1950
 ASA + clopidogrel + PCI 2112 1579 3171 2240 3410 4062
Acute stroke
 ASA 39,896 31,586 75,658 42,135 99,269 79,449
Post-acute myocardial infarction
 ASA 10,345 7701 19,853 11,173 50,593 19,029
 Statin 8822 6552 16,139 10,119 10,659 11,594
 Beta-blocker 5177 3844 9823 5575 7386 10,296
 ACE-inhibitor 4856 3612 9182 5264 6092 6771
 ASA + beta-blocker 3512 2610 6612 3835 6556 6793
 ASA + beta-blocker + statin 2717 2018 4904 3182 4351 4597
 ASA + beta-blocker + statin + ACE-
inhibitor
1849 1373 3349 2197 2704 2908
Post-acute stroke
 ACE-inhibitor 3152 2394 5642 3663 3153 3153
 ASA 2822 2121 5065 3264 9996 4833
 Statin 2397 1820 4046 3042 3427 4355
 ASA + statin 1429 1080 2382 1844 2730 2528
 ASA + statin + ACE-inhibitor 1061 803 1751 1386 1616 1545
Primary prevention of IHD and stroke
 Cholesterol lowering treatment for 
total chol. >6.2 mmol/l
532 293 791 738 605 941
 Cholesterol lowering treatment for 
total chol. >5.7 mmol/l
557 311 676 888 636 1002
 Anti-hypertension treatment for 
SBP >160 mmHg
74 42 97 102 77 124
 Combination drug treatment for 
absolute risk of CVD >35 %
67 39 88 103 69 94
 Anti-hypertension treatment for 
SBP >140 mmHg
154 88 172 234 161 263
 Combination drug treatment for 
absolute risk of CVD >25 %
77 45 95 124 80 108
 Combination drug treatment for 
absolute risk of CVD >15 %
94 55 108 157 98 132
 Combination drug treatment for 
absolute risk of CVD >5 %
141 82 153 245 148 199
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relatively more frequent follow-up visits at primary hos-
pital level for secondary prevention interventions partly 
explains higher cost-effectiveness ratios as compared 
with primary prevention interventions.
Continuing controversy about appropriate thresholds 
for cost-effectiveness ratios highlights the need for more 
empirical work in that area [50, 63, 64]. Woods et al. sug-
gested a very low CER threshold of about 50 % of GDP 
per capita compared with WHO’s recommendation of 
1–3 times GDP per capita, which translates to US$505–
US$1515 for the year 2013 [50, 63, 64]. Determining 
the appropriate cost-effectiveness ratio threshold level 
is beyond the scope of this paper, we therefore discuss 
the implications of scaling-up the intervention with the 
lowest ICER and leave the decision to policymakers to 
further select interventions that best fit the local budget 
constraint. Accordingly, combination drug treatment to 
individuals having more than 35 % absolute risk of CVD 
event is a reasonable starting point. Scale-up of this inter-
vention to a coverage level of 20 % averts 107,000 DALYs 
annually at a cost of about US$ 7 million per year. This 
is equivalent to 0.4 % of the 2010/11 annual total health 
expenditure for Ethiopia [21]. In terms of GDP per cap-
ita, the ICER is about 13 % of GDP per capita for 2013.
With the evident escalating burden from CVD and its 
risk factors [5, 7, 11, 12], investing in primary preven-
tion early on could help Ethiopia partially reduce the 
need to invest in more costly acute care and second-
ary prevention measures in the long term. Notably, the 
most cost-effective combination drug treatment based 
on an absolute risk approach could be scaled up at the 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Acute IHD (ASA,Streptokinase,B−blocker,ACE inhibitor) −hidden behind secondary prevention
Acute IHD (ASA, Clopidogrel, PCI)
Secondary prevention IHD (ASA,Statin,B−blocker,ACE inhibitor)
Secondary prevention stroke (ASA,Statin,ACE inhibitor)
Combination drug treatment for absolute risk of CVD >5% risk
Combination drug treatment for absolute risk of CVD >15% risk
Combination drug treatment for absolute risk of CVD >25% risk
Combination drug treatment for absolute risk of CVD >35% risk
Fig. 1 Probabilistic sensitivity analysis of non-dominated CVD interventions in Ethiopia
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established a solid foundation [30]. This could facilitate 
scaling up of the proposed primary prevention interven-
tions at a more modest additional resource requirement 
than originally estimated. The actual budget implication, 
however, needs to be assessed separately using appropri-
ate tools.
However, based on the probabilistic sensitivity analysis, 
the choice of intervention depends on the level of willing-
ness-to-pay. When resources are scarce (<US$7 million 
annually), a package consisting of aspirin, streptokinase, 
ACE-inhibitor and beta-blocker for AMI is a preferred 
option over combination drug treatment for an abso-
lute risk of CVD >35 %, although it ranked lower based 
on the ICER. It is also worth noting that CEA results are 
only one of the key parameters to be considered in prior-
ity setting. Policy makers need to take into account other 
important parameters for fair resource allocation, such 
as severity of disease, equity and financial risk protection 
[65].
Our study has a number of limitations. We have not 
included all possible sets of CVD interventions in our 
analysis. In the absence of country-level data on epidemi-
ology of ischemic heart disease, stroke and the risk fac-
tors (incidence, prevalence, and case fatality rate), such 
estimates were drawn from estimates for the East Africa 
region. For the same reason, the effectiveness estimates 
for interventions were drawn from studies in developed 
settings. This may introduce bias into our cost-effective-
ness ratio estimates, as it may be unrealistic to attain 
the same health benefit level from interventions in an 
Ethiopian setting; reasons for this may include differences 
in quality of health services, availability of resources and 
skilled human resources.
Interventions’ effect is assumed to be uniform across 
sub-groups with varying risk level. This may have 
resulted in an overestimation of the potential impact 
of interventions in individuals with relatively lower risk 
and underestimation of the potential impact in high risk 
group. Therefore, detection of the direction of the bias on 
the final results is not straight forward; our intuition is 
that the net effect on the final results is very minimal.
PopMod estimates interventions’ health benefits by 
tracing what would happen to the population with and 
without the interventions over a lifetime of 100  years. 
The interventions are assumed to be implemented only 
for the first 10-year period; the epidemiologic rates are 
subsequently returned to the ‘no intervention’ level. 
This only partially captures intervention health ben-
efits; possible extended benefits from interventions on 
the outcome of interest are missed, resulting in possible 
underestimation of interventions’ relative cost-effective-
ness. Intervention period of more than 10 years involves 
a high degree of uncertainty and it is difficult to predict 
how CVD interventions may look like after 10 years from 
now.
Given the healthcare provider perspective we adopted 
for the analyses, we have not considered patient and 
caregiver costs such as transportation and cost of time 
lost while seeking healthcare. In addition, out-of-pocket 






























Willingness-to-pay( in US$ million per year)
Secondary prevention IHD (ASA, ACE-inhibitor, Beta-blocker, Statin) Acute MI( ASA, Streptokinase, ACE-inhibitor, Statin)
Acute MI( ASA, Clopidogrel, PCI) Combination drug treatment for absolute risk of CVD > 35%
Secondary prevention stroke ASA, Statin, ACE-inhibitor) Combination drug treatment for absolute risk of CVD > 25%
Combination drug treatment for absolute risk of CVD > 15% Combination drug treatment for absolute risk of CVD > 5%
Fig. 2 Probabilistic sensitivity analysis of non-dominated CVD interventions in Ethiopia
Page 12 of 14Tolla et al. Cost Eff Resour Alloc  (2016) 14:10 
health spending in Ethiopia [21]. Such factors might 
influence households’ decision to access especially pre-
vention strategies that entail repeated visits to health 
facilities and this aspect requires further exploration.
For primary prevention interventions, we did not con-
sider the cost of screening all eligible individuals to iden-
tify ‘at risk’ sub-population groups. Scaling up screening 
programs could be very costly in low-income settings like 
Ethiopia [19]; therefore we included the cost of a health 
center visit and laboratory test only for those identified 
as ‘at risk’ through opportunistic screening. This would 
underestimate the potentially huge cost screening could 
entail at population level.
In addition to the proposed interventions, the potential 
benefit from sustained life style modification among the 
public cannot be over-stated for successful prevention 
and control of CVD in Ethiopia [19].
Conclusions
In Ethiopia, the escalating burden from CVD and its risk 
factors warrants timely action. We have demonstrated 
that selected packages CVD interventions could be scaled 
up in Ethiopia at a modest budget increase and that com-
bination drug treatment to individuals having more than 
35 % absolute risk of CVD event is the most cost-effective 
intervention. However, the level of willingness-to-pay 
has important implications for interventions’ probability 
of being most cost-effective. The study provides valuable 
evidence for setting priorities in an essential health care 
package for cardiovascular diseases in Ethiopia.
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